Renal transplant in HIV-positive patients: Long-term outcomes and risk factors for graft loss

Archives of Surgery

Volumn 144, Issue 1, 2009, Pages 83-86

  Locke, Jayme E ^a   Montgomery, Robert A ^a   Warren, Daniel S ^a   Subramanian, Aruna ^a   Segev, Dorry L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COLD ISCHEMIA; CONTROLLED STUDY; DONOR SELECTION; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT;

HIV SEROPOSITIVITY; HUMANS; KIDNEY TRANSPLANTATION; MIDDLE AGED; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE;

EID: 58749098774     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2008.508     Document Type: Article

References (15)

1. UNAIDS. AIDS Epidemic Update 2006. Geneva, Switzerland: UNAIDS; 2006.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta, GA: Centers for Disease Control and Prevention; 2006.
3. Wyatt CM, Murphy B. Kidney transplantation in HIV-infected patients. Semin Dial. 2005;18(6):495-498.
4. Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. 2005;67(4):1622-1629.
5. Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr. 2002;29(4):378-387.
6. Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol. 2002;13(7):1889-1893.
7. Stock PG, Roland ME. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation. 2007;84(5):563-571.
8. Hossain MM, Coull JJ, Drusano GL, Margolis DM. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res. 2002;55(1):41-52.
9. Karpas A, Lowdell M, Jacobson SK, Hill F. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. Proc Natl Acad Sci U S A. 1992;89(17):8351-8355.
10. Roy J, Paquette JS, Fortin JF, Tremblay MJ. The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 2002;46(11):3447-3455.
11. Dummer JS, Erb S, Breinig MK, et al. Infection with human immunodeficiency virus in the Pittsburgh transplant population: a study of 583 donors and 1043 recipients, 1981-1986. Transplantation. 1989;47(1):134-140.
12. Qiu J, Terasaki PI, Waki K, Cai J, Gjertson DW. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation. 2006;81(12):1658-1661.
13. Granville DJ, Tashakkor B, Takeuchi C, et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci U S A. 2004;101(5):1321-1326.
14. Bhagani S, Sweny P, Brook G. Guidelines for kidney transplantation in patients with HIV disease. HIV Med. 2006;7(3):133-139.
15. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7(12):2816-2820.